Skip to Main Content

Chapter 17: Pharmacologic Management of Parkinson’s Disease and Other Movement Disorders

Which of the following is an advantage of coadministration of carbidopa with levodopa?

a. Increase in amount of levodopa administered for clinical benefit

b. Increase in amount of levodopa diverted to peripheral tissues

c. Decreased fraction of the levodopa dose that reaches the brain

d. Increased fraction of the levodopa dose that reaches the brain

Which of the following is a pathological result of Parkinson’s disease?

a. Decreased excitatory dopaminergic input onto GABAergic cells in the striatum

b. Decreased inhibitory dopaminergic input onto GABAergic cells in the striatum

c. Decreased cholinergic input onto GABAergic cells in the striatum

d. Decreased noradrenergic input onto GABAergic cells in the striatum

Which of the following is not an adverse effect associated with levodopa or dopamine receptor agonists?

a. Anorexia

b. Orthostatic hypotension

c. Weight gain

d. Dyskinesias

Which of the following drugs is not used in the treatment of tremors?

a. Propanolol

b. Metoprolol

c. Reserpine

d. Topiramate

Which of the following drugs is an acetylcholine-blocking drug used in the treatment of Parkinson’s disease?

a. Benztropine

b. Levodopa

c. Entacapone

d. Ropinirole

Which statement is accurate regarding drug therapy in Parkinson’s disease?

a. Selegiline is a selective inhibitor of COMT.

b. The primary benefit of antimuscarinic agents is their ability to relieve bradykinesia.

c. Amantadine provides clinical benefits for 10 years.

d. Levodopa causes gastrointestinal effects in the majority of patients when the drug is given without a peripheral decarboxylase inhibitor.

Which of the following drugs is used as rescue treatment of severe acute immobility (“off periods”) in Parkinson’s disease?

...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.